Abstract:Abstract Liver cancer is the second leading cause of cancer-related death in China and worldwide, where hepatocellular carcinoma (HCC) represents the major histological type. Previous studies have demonstrated that surveillance program combining serum marker AFP and ultrasound could greatly reduce liver cancer mortality. However, it is widely recognized that AFP has lower sensitivity for early stage of the disease and the specificity is also sub-optimal, limiting its application for early detection and timely intervention. Tumor-originated circulating cell-free DNA (ctDNA), harboring cancer-related genetic and epigenetic changes, provides new opportunity for non-invasive detection of liver cancer. In this study, we have performed parallel genetic and epigenetic profiling of cfDNA from Chinese hepatocellular carcinoma patients as well as healthy individuals by targeted bisulfite sequencing and by targeted ultra-deep sequencing. For methylome profiling, we first identified HCC-specific differentially methylated regions (DMRs) and then employed machine learning approaches to build diagnostic models to classify the plasma of HCC patients from that of healthy individuals. The training cohort consists of 148 hepatocellular carcinoma cases (median age of 63) and 84 healthy individuals (median age of 60). A random forest classifier achieved an AUC of 0.94±0.04 with 10-fold cross-validation using a panel of 21 DMR markers. Meanwhile, cfDNA mutation profiling achieved a sensitivity of 50.8% and a specificity of 95.3% in the training cohort, providing an inferior diagnostic performance compared to the methylation assay. Further analyses were performed in an independent validation cohort, including HCC patients (n=112) as well as healthy control (n=96). The cfDNA methylation model achieved a sensitivity of 82.9%, and a specificity of 93.8%; all stage sensitivity excluding BCLC stage 0 was 92.8%. On the other hand, the diagnostic model based on mutation profile achieved a sensitivity of 43.8% and a specificity of 97.9% in this cohort. Furthermore, we found that the methylation model had a sensitivity of 76.6% for early HCC (BCLC stage 0 + A), while serum AFP level (>20ng/ml) had a sensitivity of 27.3%. In conclusion, our results suggest that cancer-derived abnormal methylation pattern of cfDNA provides promising biomarkers for the diagnosis of HCC with high sensitivity and specificity. Citation Format: Yuying Wang, Yupeng Wang, Ao Huang, Ruijingfang Jiang, Jianchao Zheng, Zhilong Li, Jiaxi Peng, Jianlong Sun, Chichuan Liu, Guanghui Yang, Jie Yuan, Xinrong Yang, Jian Zhou, Jia Fan. The genetic and epigenetic abnormalities of plasma cfDNA as liquid biopsy biomarkers to diagnose hepatocellular carcinoma [abstract]. In: Proceedings of the Annual Meeting of the American Association for Cancer Research 2020; 2020 Apr 27-28 and Jun 22-24. Philadelphia (PA): AACR; Cancer Res 2020;80(16 Suppl):Abstract nr 782.

Cell-free DNA 5-hydroxymethylcytosine profiles of long non-coding RNA genes enable early detection and progression monitoring of human cancers

Deoxyribonucleic Acid 5-Hydroxymethylation in Cell-Free Deoxyribonucleic Acid, a Novel Cancer Biomarker in the Era of Precision Medicine

Early Detection of Non-Small Cell Lung Cancer with Novel 5-Hydroxymethylcytosine DNA Markers: Discovery, Tissue Validation, and Pilot Testing in Plasma

5-Hydroxymethylome in Circulating Cell-free DNA as A Potential Biomarker for Non-small-cell Lung Cancer

5-Hydroxymethylcytosine signatures in circulating cell-free DNA as diagnostic biomarkers for human cancers

DNA 5-Hydroxymethylcytosines from Cell-free Circulating DNA As Diagnostic Biomarkers for Human Cancers

Identification of a 5-Hydroxymethylation Signature in Circulating Cell-Free DNA for the Noninvasive Detection of Colorectal Cancer

5-Hydroxymethylcytosine Signatures in Cell-Free DNA Provide Information about Tumor Types and Stages

Cell-Free DNA 5-Hydroxymethylcytosine Signatures for Lung Cancer Prognosis

5-Hydroxymethylcytosine Signatures in Circulating Cell-Free DNA as Diagnostic Biomarkers for Late-Onset Alzheimer’s Disease

A 5-Hydroxymethylcytosine-based Noninvasive Model for Early Detection of Colorectal Carcinomas and Advanced Adenomas: the METHOD-2 Study

A Highly Sensitive and Specific Non‐Invasive Test through Genome‐Wide 5‐Hydroxymethylation Mapping for Early Detection of Lung Cancer

5-Hydroxymethylcytosines from Circulating Cell-free DNA As Diagnostic and Prognostic Markers for Hepatocellular Carcinoma

5-Hydroxymethylated Biomarkers in Cell-Free DNA Predict Occult Colorectal Cancer up to 36 Months Before Diagnosis in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial

Multi-cancer detection and tissue of origin determination based on 5-hydroxymethylcytosine biomarkers in circulating cell-free DNA.

Genome-wide Mapping of 5-Hydroxymethylcytosines in Circulating Cell-Free DNA As a Non-Invasive Approach for Early Detection of Hepatocellular Carcinoma

5-Hydroxymethylcytosine profiling from genomic and cell-free DNA for colorectal cancers patients

Genome-wide discovery and validation of diagnostic DNA methylation-based biomarkers for hepatocellular cancer detection in circulating cell free DNA

Genome-scale detection of hypermethylated CpG islands in circulating cell-free DNA of hepatocellular carcinoma patients

Identification of Long Noncoding Rnas for the Detection of Early Stage Lung Squamous Cell Carcinoma by Microarray Analysis

Abstract 782: the Genetic and Epigenetic Abnormalities of Plasma Cfdna As Liquid Biopsy Biomarkers to Diagnose Hepatocellular Carcinoma